The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

SBRT may ease toxicity, but the lower doses could come at the expense of cancer control, new data indicate. Experts suggest a ...

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive ...

Adding external-beam radiation to brachytherapy does not improve 5-year freedom from progression (FFP) for men with intermediate-risk prostate cancer, but it does increase treatment toxicity. The ...

Autonomic nerve invasion may be simple method of identifying which patients with intermediate-risk T3a prostate cancer who have negative surgical margins after radical prostatectomy are at increased ...

For patients with intermediate-risk localized prostate cancer, stereotactic body radiation therapy (SBRT) yields favorable bowel health-related quality of life (HRQOL).

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) ...